UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
AMENDMENT NO. 4
to
SCHEDULE TO
TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1)
OF THE SECURITIES EXCHANGE ACT OF 1934
SurModics, Inc.
(Name Of Subject Company (Issuer) And Filing Person (Offeror))
Common Stock, par value $0.05 per share
(Title of Class of Securities)
868873100
(CUSIP Number of Common Stock)
Bryan K. Phillips, Esq.
Senior Vice President, General Counsel and Secretary
9924 West 74th Street
Eden Prairie, Minnesota 55344
(952) 500-7000
(Name, address and telephone number of person authorized to receive notices and communications on behalf of filing persons)
With a copy to:
Douglas P. Long, Esq.
Faegre Baker Daniels LLP
2200 Wells Fargo Center
90 South 7th Street
Minneapolis, Minnesota 55402
(612) 766-7000
CALCULATION OF FILING FEE
|
| ||
| Transaction Valuation* | Amount Of Filing Fee** | |
| $55,000,000 |
$6,303.00 | |
|
| ||
|
| ||
| * | The transaction value is estimated only for purposes of calculating the filing fee. This amount is based on the offer to purchase for not more than $55 million in aggregate of up to 3,235,294 shares of common stock, $0.05 par value, at the minimum tender offer price of $17.00 per share. |
| ** | Previously Paid. The amount of the filing fee, calculated in accordance with Rule 0-11 under the Securities Exchange Act of 1934, as amended, as modified by Fee Rate Advisory No. 3 for fiscal year 2012, equals $114.60 per million dollars of the value of the transaction. |
| ¨ | Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer. |
Check the appropriate boxes below to designate any transactions to which the statement relates:
| ¨ | third-party tender offer subject to Rule 14d-1. |
| x | issuer tender offer subject to Rule 13e-4. |
| ¨ | going-private transaction subject to Rule 13e-3. |
| ¨ | amendment to Schedule 13D under Rule 13d-2. |
Check the following box if the filing is a final amendment reporting the results of the tender offer: x
If applicable, check the appropriate box(es) below to designate the appropriate rule provision(s) relied upon:
| ¨ | Rule 13e-4(i) (Cross-Border Issuer Tender Offer) |
| ¨ | Rule 14d-1(d) (Cross-Border Third Party Tender Offer) |
SCHEDULE TO
This Amendment No. 4 to Schedule TO (“Amendment No. 4”) amends and supplements the Tender Offer Statement on Schedule TO, and the Offer to Purchase dated August 6, 2012 filed as exhibit (a)(1)(i) thereto, originally filed with the United States Securities and Exchange Commission (the “SEC”) by SurModics, Inc., a Minnesota corporation (“SurModics” or the “Company”) on August 6, 2012, as amended on August 9, 2012 by Amendment No. 1 to Schedule TO (“Amendment No. 1”), on August 27, 2012 by Amendment No. 2 to Schedule TO (“Amendment No. 2”) and on September 6, 2012 by Amendment No. 3 to Schedule TO (“Amendment No. 3”), in connection with the Company’s offer to purchase up to $55 million in value of shares of its common stock, $0.05 par value per share (the “Shares”), at a price not greater than $19.00 nor less than $17.00 per Share, to the seller in cash, less any applicable withholding taxes and without interest.
Only those items amended are reported in this Amendment No. 4. Except as specifically provided herein, the information contained in the Schedule TO, Amendment No. 1, Amendment No. 2, Amendment No. 3 and the Offer to Purchase remains unchanged and this Amendment No. 4 does not modify any of the information previously reported on the Schedule TO, Amendment No. 1, Amendment No. 2 and Amendment No. 3. You should read this Amendment No. 4 together with the Schedule TO, Amendment No. 1, Amendment No. 2, Amendment No. 3, the Offer to Purchase and the Letter of Transmittal.
| ITEM 11. | ADDITIONAL INFORMATION |
Item 11 of the Schedule TO is hereby amended and supplemented by adding the following:
On September 11, 2012, the Company issued a press release announcing the final results of the Offer, which expired at 5:00 p.m., New York City time, on Wednesday, September 5, 2012. A copy of the press release is filed as Exhibit (a)(5)(vi) to the Schedule TO and is incorporated herein by reference.
| ITEM 12. | EXHIBITS |
Item 12 is amended and supplemented by adding the following exhibit as follows:
| (a)(5)(vi) |
Press Release dated September 11, 2012. |
SIGNATURES
After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Schedule TO is true, complete and correct.
| SurModics, Inc. | ||||
| Dated: September 11, 2012 | By: | /s/ Gary R. Maharaj | ||
| Name: | Gary R. Maharaj | |||
| Title: | President and Chief Executive Officer | |||
Exhibit 99(a)(5)(vi)
SurModics Announces Final Results of its Modified Dutch Tender Offer
EDEN PRAIRIE, Minn – (BUSINESS WIRE) – September 11, 2012 – SurModics, Inc. (Nasdaq:SRDX), a leading provider of surface modification and in vitro diagnostic technologies to the healthcare industries, today announced the final results of its modified Dutch auction tender offer for up to $55.0 million in value of its common stock, which expired at 5:00 p.m., New York City time, on Wednesday, September 5, 2012. In accordance with the terms and conditions of the tender offer, SurModics has accepted for purchase 2,894,736 shares of its common stock at a price of $19.00 per share, for an aggregate cost of $55 million, excluding fees and expenses relating to the tender offer. These shares represent approximately 16.5% of SurModics’ currently outstanding common stock.
Based on the final count by American Stock Transfer & Trust Company, LLC, the Depositary for the tender offer, approximately 2.93 million shares of SurModics’ common stock were properly tendered and not properly withdrawn at or below the purchase price of $19.00 per share. Since the offer was oversubscribed, the number of shares that SurModics will purchase from each tendering shareholder will be pro-rated. Based upon the number of shares tendered, the proration factor will be approximately 98.7%.
The Depositary will promptly issue payment for the shares accepted for purchase in accordance with the terms and conditions of the Offer. Shares tendered and not accepted for purchase will be returned promptly to shareholders by the Depositary.
As a result of the settlement of the tender offer, SurModics has 14.65 million shares of common stock outstanding.
Shareholders who have questions may call Citigroup Global Markets Inc., the dealer-manager for the Offer, at 800-531-8365, or MacKenzie Partners, Inc., the information agent for the Offer, at 800-322-2885.
About SurModics, Inc.
SurModics’ mission is to exceed our customers’ expectations and enhance the well-being of patients by providing the world’s foremost, innovative surface modification technologies and in vitro diagnostic chemical components. The Company partners with the world’s leading and emerging medical device, diagnostic and life science companies to develop and commercialize innovative products designed to improve patient diagnosis and treatment. Core offerings include surface modification coating technologies that impart lubricity, prohealing, and biocompatibility capabilities; and components for in vitro diagnostic test kits and microarrays. SurModics is headquartered in Eden Prairie, Minnesota.
CONTACT:
SurModics, Inc.
Tim Arens, 952-500-7000
Vice President of Finance and interim Chief Financial Officer
- # # # -